Skip to main content
. 2018 Jul 31;51(2):649–663. doi: 10.4143/crt.2018.270

Fig. 4.

Fig. 4.

(A) Disease-free survival (DFS) according to changes of tumor infiltrating lymphocyte during neoadjuvant chemotherapy (NAC). (B) DFS according to change of tumor cell programmed death ligand-1 (PD-L1) expression change during NAC. (C) DFS according to change of stromal cell PD-L1 expression during NAC.